STOCK TITAN

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced its participation in the H.C.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced its participation in the H.C. Wainwright 8th Annual MASH Virtual Investor Conference. The event will feature a fireside chat scheduled for 2:00 P.M. ET on Monday, Oct. 7, 2024. The session will be webcast live and can be accessed through a provided link or via Madrigal's Investor Relations Events page. A replay of the webcast will be available after the event.

Loading...
Loading translation...
Argus Session date unavailable
-0.09% session move Open Argus
Details

News Market Reaction – MDGL

The recorded move for MDGL in the trading session of this news was -0.09%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024.

The fireside chat will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Madrigal Pharmaceuticals participating in the H.C. Wainwright 8th Annual MASH Virtual Investor Conference?

Madrigal Pharmaceuticals will participate in the conference on Monday, Oct. 7, 2024, at 2:00 P.M. ET.

How can I access the live webcast of Madrigal Pharmaceuticals' fireside chat at the H.C. Wainwright 8th Annual MASH Investor Conference?

The live webcast can be accessed through a provided link or by visiting Madrigal's Investor Relations Events page.

Will there be a replay available for Madrigal Pharmaceuticals' fireside chat at the H.C. Wainwright 8th Annual MASH Investor Conference?

Yes, a replay of the webcast will be available after the event.

What is the stock symbol for Madrigal Pharmaceuticals?

The stock symbol for Madrigal Pharmaceuticals is MDGL.

Keep reading